Exocrine Pancreatic Insufficiency (EPI) Epidemiology Forecast Report 2021-2030 – ResearchAndMarkets.com
DUBLIN–(BUSINESS WIRE)–The “Exocrine Pancreatic Insufficiency (EPI) – Epidemiology Forecast – 2030” report has been added to ResearchAndMarkets.com’s offering.
The disease epidemiology covered in the report provides historical as well as forecasted epidemiology segmented by Prevalence of Causative Indications of EPI and Prevalence of Exocrine Pancreatic Insufficiency scenario of Exocrine Pancreatic Insufficiency (EPI) in the 7MM covering the United States, EU5 countries (Germany, France, Italy, Spain, and United Kingdom) and Japan from 2017 to 2030.
Exocrine Pancreatic Insufficiency (EPI) Detailed Epidemiology Segmentation
- In the 7MM, the highest prevalence of Causative Indications of EPI was observed in Type 2 Diabetes Mellitus which was estimated to be 67,892,836 cases in 2017 during the forecast period (2020-2030).
- As per the estimates in Japan, 61,961, 66,261, 11,721, 25,319 patients were affected by Acute Pancreatitis, Chronic Pancreatitis, Cystic Fibrosis and Unresectable Pancreatic Cancer in 2017, respectively, which are anticipated to increase in the forecast period.
- Acute Pancreatitis, Chronic Pancreatitis, Cystic Fibrosis and Unresectable Pancreatic Cancer are assumed to play the foremost role in the development of EPI.
Scope of the Report
- The report covers the descriptive overview of Exocrine Pancreatic Insufficiency (EPI), explaining its causes, signs and symptoms, pathophysiology.
- The report provides insight into the 7MM historical and forecasted patient pool covering the United States, EU5 countries (Germany, France, Italy, Spain, and United Kingdom) and Japan.
- The report assesses the disease risk and burden and highlights the unmet needs of Exocrine Pancreatic Insufficiency (EPI).
- The report provides the segmentation of the disease epidemiology for 7MM by Total Prevalent Cases of Exocrine Pancreatic Insufficiency (EPI), Total Diagnosed and Treated Cases of Exocrine Pancreatic Insufficiency (EPI).
Report Highlights
- Eleven Year Forecast of Exocrine Pancreatic Insufficiency (EPI)
- 7MM Coverage
- Prevalence of Causative Indications of EPI
- Prevalence of Exocrine Pancreatic Insufficiency
Key Questions Answered
- What is the disease risk, burden and unmet needs of Exocrine Pancreatic Insufficiency (EPI)?
- What is the historical Exocrine Pancreatic Insufficiency (EPI) patient pool in the United States, EU5 (Germany, France, Italy, Spain, and the UK) and Japan?
- What would be the forecasted patient pool of Exocrine Pancreatic Insufficiency (EPI) at the 7MM level?
- What will be the growth opportunities across the 7MM with respect to the patient population pertaining to Exocrine Pancreatic Insufficiency (EPI)?
- Out of the above-mentioned countries, which country would have the highest prevalent population of Exocrine Pancreatic Insufficiency (EPI) during the forecast period (2020-2030)?
- At what CAGR the population is expected to grow across the 7MM during the forecast period (2020-2030)?
Key Assessments
- Patient Segmentation
- Disease Risk and Burden
- Risk of disease by the segmentation
- Factors driving growth in a specific patient population
Study Period: 2017-2030
Key Topics Covered:
1 Key Insights
2 Executive Summary
3 SWOT Analysis
4 Exocrine Pancreatic Insufficiency (EPI) Overview at a Glance
4.1 Patient Share (%) Distribution of Exocrine Pancreatic Insufficiency (EPI) in 2017
4.2 Patient Share (%) Distribution of Exocrine Pancreatic Insufficiency (EPI) in 2030
5 Disease Background and Overview: Exocrine Pancreatic Insufficiency (EPI)
5.1 Introduction
5.2 Biology and pathology of Exocrine Pancreatic Insufficiency
5.3 Pathophysiology of EPI
5.4 Causes and Risk Factors of EPI
5.4.1 EPI caused by pancreatic disorders
5.4.2 EPI caused by extrapancreatic disorders
5.5 Serum nutritional markers for prediction of pancreatic exocrine insufficiency in chronic pancreatitis
5.5.1 Disorders of Carbohydrate Metabolism
5.5.1 Disorders of Lipid Metabolism
5.6 Diagnosis
5.6.1 Fecal elastase-1 test (FE-1)
5.6.2 Serum trypsinogen
5.6.3 Fecal chymotrypsin
5.6.4 Breath tests
5.6.5 Coefficient of fat absorption (CFA)
5.6.6 Preoperative Evaluation
5.6.7 Direct pancreatic function test
5.6.8 Secretin-enhanced magnetic resonance cholangiopancreatography (MRCP)
5.6.9 Differential Diagnosis of exocrine pancreatic insufficiency
6 Recognized Establishments
7 Epidemiology and Patient Population
7.1 Key Findings
7.2 7 Major Markets
7.2.1 Prevalence of Causative Indications of EPI in the 7MM
7.2.2 Prevalence of Exocrine Pancreatic Insufficiency in the 7MM
8 Country-wise Epidemiology of Exocrine Pancreatic Insufficiency (EPI)
8.1 Assumption and Rationale
8.1 United States
8.1.1 Prevalence of Causative Indications of EPI in the United States
8.1.2 Prevalence of Exocrine Pancreatic Insufficiency in the United States
8.2 EU5 Countries
8.2.1 Assumption and Rationale
8.3 Germany
8.4 France
8.5 Italy
8.6 Spain
8.7 The United Kingdom
8.8 Japan
9 Appendix
For more information about this report visit https://www.researchandmarkets.com/r/89y1k1
Contacts
ResearchAndMarkets.com
Laura Wood, Senior Press Manager
[email protected]
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
